Clinical Trial Update: Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on ustekinumab for inflammatory pathology in Leukocyte adhesion deficiency type 1 (LAD1); the Phase 1/2 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukocyte Adhesion Deficiency Type

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: LAD1 | Phase 1, Phase 2 | Status: COMPLETED